Basic Information
| LncRNA/CircRNA Name | SSTR5-AS1 |
| Synonyms | NA |
| Region | GRCh38_16:1064093-1078731 |
| Ensemble | ENSG00000261713 |
| Refseq | NR_027242 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | 5-Aza-dC, TSA | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | laryngeal squamous cell cancer |
| ICD-0-3 | C32.3 |
| Methods | Microarray, qPCR, Western blot, RIP |
| Sample | Human laryngeal carcinoma cell lines AMC-HN-8, TU212, TU686, and TU177, Primary LSCC tissues and corresponding adjacent normal tissues |
| Expression Pattern | down-regulated |
| Function Description | Downregulation of SSTR5 is detected in LSCC tissues and laryngeal carcinoma cells. Aberrant DNA hypermethylation of the CpG sites clustered in the exon 1 and accumulation of inactive histone modifcations at SSTR5 promoter region may be epigenetic mechanisms for its inactivation in LSCC. SSTR5-AS1 may play antitumor role in LSCC and may be regulated by the hypermethylation of the same CpG sites with SSTR5. SSTR5-AS1 inhibits laryngeal carcinoma cells proliferation, migration, and invasion. SSTR5-AS1 increases the enrichment of MLL3 and H3K4me3 at the promoter region of SSTR5 by interacting with MLL3 and further induces the transcription of SSTR5. Furthermore, SSTR5-AS1 interacts with and recruits TET1 to its target gene E-cadherin to activate its expression. |
| Pubmed ID | 31196171 |
| Year | 2019 |
| Title | Aberrant methylation-mediated downregulation of lncRNA SSTR5-AS1 promotes progression and metastasis of laryngeal squamous cell carcinoma |
External Links
| Links for SSTR5-AS1 | GenBank HGNC NONCODE |
| Links for laryngeal squamous cell cancer | OMIM COSMIC |